Lower-Risk MDS: A Review of Data from the ASH 2022 Annual Meeting - Episode 1

First- and Second-Line Treatment Options in Lower-Risk MDS

, , ,

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Now Viewing
EP. 1: First- and Second-Line Treatment Options in Lower-Risk MDS
EP. 2: Luspatercept in Lower-Risk MDS
EP. 3: Emerging Therapies for Lower-Risk MDS